Madrigal pharmaceuticals to announce topline results from the phase 3 maestro-nash study of resmetirom on monday, december 19th

Conshohocken, pa., dec. 18, 2022 (globe newswire) -- madrigal pharmaceuticals, inc. (nasdaq: mdgl), a clinical-stage biopharmaceutical company pursuing novel therapeutics for nonalcoholic steatohepatitis (nash), plans to announce topline results from the phase 3 maestro-nash study of resmetirom on monday, december 19th, 2022.
MDGL Ratings Summary
MDGL Quant Ranking